Loading clinical trials...
Loading clinical trials...
To assess safety and efficacy of the patients with MR4 therapy in GVHD prophylaxis study who are eligible for the administration after 100 days post transplant (up to 1 year)
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Astellas Pharma Inc
NCT06008808 · Graft Vs Host Disease, Graft-versus-host-disease, and more
NCT06705062 · Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease
NCT07070674 · Acute Graft-versus-Host Disease
NCT01804686 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and more
NCT00001529 · Graft-Versus-Host Disease, Graft-versus-leukemia, and more
Chubu Region
Hokkaido Region
Kanto Region
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions